Lindsay K. Ryland, Ph.D.
Affiliations: | 2011 | Pharmacology | Pennsylvania State University, State College, PA, United States |
Area:
Pharmacology, NanoscienceGoogle:
"Lindsay Ryland"Mean distance: 17811
Parents
Sign in to add mentor| Mark Kester | grad student | 2011 | Penn State | |
| (Differential mechanisms of cell death induction via delivery of therapeutic nanoliposomal ceramide in leukemias.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Ryland LK, Doshi UA, Shanmugavelandy SS, et al. (2013) C6-ceramide nanoliposomes target the Warburg effect in chronic lymphocytic leukemia. Plos One. 8: e84648 |
| LeBlanc F, Liu X, Fox T, et al. (2012) Targeting Sphingosine Kinase 1 in NK-LGL Leukemia Blood. 120: 1313-1313 |
| Liao A, Broeg K, Fox T, et al. (2011) Therapeutic efficacy of FTY720 in a rat model of NK-cell leukemia. Blood. 118: 2793-800 |
| Ryland LK, Fox TE, Liu X, et al. (2011) Dysregulation of sphingolipid metabolism in cancer. Cancer Biology & Therapy. 11: 138-49 |
| Liu X, Ryland L, Yang J, et al. (2010) Targeting of survivin by nanoliposomal ceramide induces complete remission in a rat model of NK-LGL leukemia. Blood. 116: 4192-201 |
| Yang J, Liu X, Nyland SB, et al. (2010) Platelet-derived growth factor mediates survival of leukemic large granular lymphocytes via an autocrine regulatory pathway. Blood. 115: 51-60 |
| Liu X, Ryland L, Yang J, et al. (2008) Systemic Delivery of Nanoliposomal Ceramide Displays Anti-Leukemic Activity in a Rat Model of Large Granular Lymphocytic Leukemia Blood. 112: 3999-3999 |